# PDS Biotechnology Corp. PDSB

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001472091

# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $30.5M |
| **Warnings** | short runway, thin data; fortress balan...<br>not computable: degenerate inputs, distress |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Apr 28, 2026<br>192 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $1.16<br>2026-11-05; market equity $64.6M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 30, 2026*

We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases. have the potential to overcome limitations of current immunotherapy approaches through effective conversion of the immune suppressive tumor to an immunogenic microenvironment in addition to the induction of the right type, potency and quantity of tumor-targeting killer (CD8) T cells.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 24.5** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | | |
| *a prior annual debt, equity, and cash observation is required* | | | | | | |
| Accruals ratio | (17.8%) | (6.6%) | | 24.5 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 66.9** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (25.61) | (0.37) | | 78.2 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 2.98x | 2.94x | | 55.7 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 76.2** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.0% | | | | |
| *four annual observations are required; found 0* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 6* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | (26.6%) | 2.2% | | 90.6 | 696 | 2025-12-31 |
| Net share issuance, one year | 23.0% | 2.5% | | 61.8 | 630 | 2026-03-23 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 4.0 months |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 124,723,421 USD; Altman Z is not used |

## What the price implies

*at the 2026-11-05 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (19.7%) | (2.1%) | 37 |
| Distance from 52-week high | (26.9%) | (30.4%) | 54 |
| EBIT to enterprise value | (42.1%) | (1.5%) | 15 |
| Free cash flow yield | (42.4%) | (1.0%) | 16 |
| Book value to price | (0.05) | 0.29 | 8 |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | 92.2% | 21.4% | 75 |
| Relative strength against the sector, log excess return | (0.39) | (0.19) | 37 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $5.6M |
| Operating cash flow, four quarters | -$16.8M |
| Months of runway | 4.0 |
| Days since last periodic filing | 85 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $4.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | -$26.5M | 2015-12-31 | 2018-03-01 | 10-K | 18-011218 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$29.2M | 2015-12-31 | 2018-03-01 | 10-K | 18-011218 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$1.1M | 2015-12-31 | 2018-03-01 | 10-K | 18-011218 |
| 4 | total debt | us-gaap:LongTermDebt | $5.5M | 2015-12-31 | 2016-03-08 | 10-K | 16-056994 |
| 5 | book equity | us-gaap:StockholdersEquity | $122.5M | 2015-12-31 | 2018-03-01 | 10-K | 18-011218 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $130.2M | 2015-12-31 | 2018-03-01 | 10-K | 18-011218 |
| 7 | net income | us-gaap:NetIncomeLoss | -$34.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 8 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$27.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 9 | assets | us-gaap:Assets | $30.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 10 | assets | us-gaap:Assets | $45.4M | 2024-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 11 | current assets | us-gaap:AssetsCurrent | $28.3M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 12 | current liabilities | us-gaap:LiabilitiesCurrent | $9.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 13 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$216.6M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 14 | operating income | us-gaap:OperatingIncomeLoss | -$31.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 15 | book equity | us-gaap:StockholdersEquity | $9.3M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 16 | liabilities | us-gaap:Liabilities | $21.2M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 17 | depreciation amortization | us-gaap:Depreciation | $53,116 | 2015-12-31 | 2018-03-01 | 10-K | 18-011218 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$43.0M | 2023-12-31 | 2025-03-27 | 10-K | 25-010717 |
| 19 | interest expense | us-gaap:InterestExpense | $4.2M | 2023-12-31 | 2024-03-28 | 10-K | 24-016265 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $0 | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 21 | depreciation amortization | us-gaap:Depreciation | $21,836 | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 22 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$35.7M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 23 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$1.2M | 2025-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 24 | current assets | us-gaap:AssetsCurrent | $45.1M | 2024-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $17.1M | 2024-12-31 | 2026-03-30 | 10-K | 26-012030 |
| 26 | assets | us-gaap:Assets | $59.4M | 2023-12-31 | 2025-03-27 | 10-K | 25-010717 |
| 27 | assets | us-gaap:Assets | $77.0M | 2022-12-31 | 2024-03-28 | 10-K | 24-016265 |
| 28 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 55,815,653 | 2026-03-23 | 2026-04-28 | 10-K/A | 26-017461 |
| 29 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 45,395,851 | 2025-03-20 | 2025-03-27 | 10-K | 25-010717 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.